---
title: "Werewolf Therapeutics (HOWL.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HOWL.US/norm.md"
symbol: "HOWL.US"
name: "Werewolf Therapeutics"
parent: "https://longbridge.com/en/quote/HOWL.US.md"
datetime: "2026-05-20T23:05:27.030Z"
locales:
  - [en](https://longbridge.com/en/quote/HOWL.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HOWL.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HOWL.US/norm.md)
---

# Werewolf Therapeutics (HOWL.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.2800 | -0.1966 | -0.3600 | -0.4000 | -0.4035 |
| ROE | -292.53% | -123.21% | -184.25% | -145.65% | -110.72% |
| Revenue | - | - | - | - | - |
| Net income | -13.53M | -8.38M | -16.37M | -17.98M | -18.09M |
| Operating income | -13.27M | -9.42M | -15.73M | -17.54M | -17.99M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 58.02M | 69.40M | 79.63M | 92.57M | 107.24M |
| Leverage | 4.76 | 2.80 | 2.69 | 2.23 | 1.87 |
| BVPS | 0.2511 | 0.5104 | 0.6264 | 0.9146 | 1.28 |
| Turnover | - | - | 0.0000 | 0.0000 | 0.0080 |
| Cash & STI | 46.45M | 57.05M | 65.71M | 77.60M | 92.04M |
| Inv & Rec | - | - | - | - | - |
| LT assets | 9.29M | 9.90M | 10.51M | 11.11M | 11.71M |
| Net debt | -37.63M | -47.62M | -28.41M | -40.45M | -55.03M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -10.60M | -11.02M | -15.16M | -15.16M | -18.95M |
| Investing CF | - | - | - | - | - |
| Financing CF | - | 2.37M | 3.27M | 388000.00 | - |
| Free CF | -6.13M | 20.95M | -9.03M | -8.13M | -12.52M |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |